Compare MBI & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBI | TNGX |
|---|---|---|
| Founded | 1973 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.5M | 1.4B |
| IPO Year | 1987 | N/A |
| Metric | MBI | TNGX |
|---|---|---|
| Price | $6.88 | $11.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $8.50 | ★ $12.50 |
| AVG Volume (30 Days) | 356.6K | ★ 2.5M |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $93,000,000.00 | $66,501,000.00 |
| Revenue This Year | N/A | $52.80 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 285.71 | 53.29 |
| 52 Week Low | $3.86 | $1.03 |
| 52 Week High | $8.26 | $11.20 |
| Indicator | MBI | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 39.58 | 79.22 |
| Support Level | $6.53 | $8.66 |
| Resistance Level | $7.20 | $9.16 |
| Average True Range (ATR) | 0.29 | 0.62 |
| MACD | -0.05 | 0.22 |
| Stochastic Oscillator | 26.14 | 93.96 |
MBIA Inc provides financial guaranty insurance for municipal bonds and asset-backed securities in the United States and internationally. It offers an unconditional guarantee to repay the principal and interest on these securities if the issuer defaults. MBIA insures bonds sold in the primary and secondary markets, as well as those held in unit investment trusts and mutual funds. It operates in three segments: the United States Public Finance Insurance, which derives maximum revenue, Corporate, and International & Structured Finance Insurance. U.S. public finance insurance portfolio is managed through the National Public Finance Guarantee Corporation. International & structured finance insurance business is managed through MBIA Insurance Corporation and its subsidiary.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.